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Olfactory dysfunction is common in subjects with Parkinson’s disease. The pathophysiology of such dysfunction, however,
remains poorly understood. Neurodegeneration within central regions involved in odour perception may contribute to olfactory
dysfunction in Parkinson’s disease. Central cholinergic deﬁcits occur in Parkinson’s disease and cholinergic neurons innervate
regions, such as the limbic archicortex, involved in odour perception. We investigated the relationship between performance on
an odour identiﬁcation task and forebrain cholinergic denervation in Parkinson’s disease subjects without dementia. Fifty-eight
patients with Parkinson’s disease (mean Hoehn and Yahr stage 2.50.5) without dementia (mean Mini-Mental State
Examination, 29.01.4) underwent a clinical assessment, [
11C]methyl-4-piperidinyl propionate acetylcholinesterase brain posi-
tron emission tomography and olfactory testing with the University of Pennsylvania Smell Identiﬁcation Test. The diagnosis of
Parkinson’s disease was conﬁrmed by [
11C]dihydrotetrabenazine vesicular monoamine transporter type 2 positron emission
tomography. We found that odour identiﬁcation test scores correlated positively with acetylcholinesterase activity in the
hippocampal formation (r=0.56, P50.0001), amygdala (r=0.50, P50.0001) and neocortex (r=0.46, P=0.0003). Striatal mono-
aminergic activity correlated positively with odour identiﬁcation scores (r=0.30, P50.05). Multiple regression analysis includ-
ing limbic (hippocampal and amygdala) and neocortical acetylcholinesterase activity as well as striatal monoaminergic activity,
using odour identiﬁcation scores as the dependent variable, demonstrated a signiﬁcant regressor effect for limbic acetylcholin-
esterase activity (F=10.1, P50.0001), borderline for striatal monoaminergic activity (F=1.6, P=0.13), but not signiﬁcant for
cortical acetylcholinesterase activity (F=0.3, P=0.75). Odour identiﬁcation scores correlated positively with scores on cognitive
measures of episodic verbal learning (r=0.30, P50.05). These ﬁndings indicate that cholinergic denervation of the limbic
archicortex is a more robust determinant of hyposmia than nigrostriatal dopaminergic denervation in subjects with moderately
severe Parkinson’s disease. Greater deﬁcits in odour identiﬁcation may identify patients with Parkinson’s disease at risk for
clinically signiﬁcant cognitive impairment.
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Abbreviations: AChE = acetylcholinesterase; UPSIT = University of Pennsylvania Smell Identiﬁcation Test; VMAT2 = vesicular
monoamine transporter type 2
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The pathophysiology of hyposmia in Parkinson’s disease is poorly
understood. Neuronal degeneration with deposition of -synuclein
within the olfactory bulb and anterior olfactory nucleus occurs
early in Parkinson’s disease (Braak et al., 2002; Hawkes et al.,
2009). There is evidence also of -synuclein pathology within
the limbic rhinencephalon (Silveira-Moriyama et al., 2009).
Deﬁcits in olfactory function in Parkinson’s disease are described
in odour identiﬁcation, odour discrimination, threshold detection
and odour recognition memory (Mesholam et al., 1998). While
there is some evidence that odour identiﬁcation and discrimination
may be impaired independently of olfactory detection threshold
sensitivity in Parkinson’s disease (e.g. Boesveldt et al., 2009),
effect sizes are large in Parkinson’s disease for all three of these
nominally distinct domains (Mesholam et al., 1998), and tests of
odour identiﬁcation, detection and discrimination typically share
considerable variance (Doty et al., 1994). Odour discrimination
tasks may preferentially recruit the hippocampus, possibly reﬂect-
ing its role in the working memory element of such tasks (Kareken
et al., 2003). We reported previously that impaired odour identi-
ﬁcation in early Parkinson’s disease is correlated with hippocampal
more than amygdala or striatal dopaminergic denervation (Bohnen
et al., 2008). These ﬁndings suggest that hippocampal dopamin-
ergic denervation and/or dysfunction may contribute to olfactory
dysfunction in early Parkinson’s disease. Olfactory impairments,
however, are not affected by dopaminergic medications, and cor-
relate poorly, if at all, with disease stage or duration of motor
features (Doty et al., 1988; Tissingh et al., 2001; Herting et al.,
2008), suggesting a ‘ﬂoor’ phenomenon in hyposmia with respect
to dopaminergic degeneration in advancing Parkinson’s disease.
Diminished olfactory performance in non-demented subjects with
Parkinson’s disease, however, may indicate increased risk of visual
hallucinations, implying higher risk for developing dementia
2–6years later, features that cannot be attributed easily to dopa-
minergic neuron degeneration (Stephenson et al., 2008).
Hyposmia occurs also in Alzheimer’s disease (Doty et al., 1987)
and increases with severity of dementia (Murphy et al., 1990;
Serby et al., 1991; Wilson et al., 2009). Higher density of entorh-
inal cortex and hippocampal neuroﬁbrillary tangles correlate with
greater deﬁcits of odour identiﬁcation, suggesting a role for hip-
pocampal dysfunction in Alzheimer’s disease hyposmia (Wilson
et al., 2007). Loss of basal forebrain cholinergic neurons is an
important feature of Alzheimer’s disease (Yan and Feng, 2004),
with early involvement of septohippocampal projections (Lehericy
et al., 1993). Cholinergic system degeneration is also an early
feature of Parkinson’s disease and worsens with the appearance
of dementia (Ruberg et al., 1986; Shimada et al., 2009). It is
possible that limbic cholinergic denervation may also be a con-
tributory factor to Parkinson’s disease hyposmia. If so, hyposmia
would be most marked in those subjects with evidence of cogni-
tive dysfunction. The goal of this study was to test the hypothesis
that deﬁcits in odour identiﬁcation would correlate with central
cholinergic denervation, especially of the hippocampus, and that
odour identiﬁcation scores correlate with cognitive performance in
Parkinson’s disease.
Materials and methods
Subjects and clinical test battery
This cross-sectional study involved 58 subjects with Parkinson’s disease
(49 males and 9 females), mean age 69.07.6 (range 51–83) years
and 26 control non-Parkinson’s disease subjects (17 males and 9 fe-
males), mean age 67.210.5 (range 50–84) years. Patients with
Parkinson’s disease met the UK Parkinson’s Disease Society Brain
Bank Research Centre clinical diagnostic criteria (Hughes et al.,
1992). The diagnosis of Parkinson’s disease was also conﬁrmed
by the presence of nigrostriatal dopaminergic denervation on
(+)-[
11C]dihydrotetrabenazine vesicular monoamine type 2 (VMAT2)
positron emission tomography (PET). Dihydrotetrabenazine binding is a
good marker of nigrostriatal dopaminergic denervation, as over 95%
of the striatal signal is attributable to dopaminergic vesicular binding
and shows excellent correlation with tyrosine hydroxylase-positive
neuron density in the substantia nigra pars compacta (Vander Borght
et al., 1995). Thirty-one Parkinson’s disease subjects were taking a
combination of dopamine agonist and carbidopa-levodopa medica-
tions, 18 were using carbidopa-levodopa alone, 7 were taking dopa-
mine agonists alone and 2 were not on dopaminergic drugs. No
subjects were on anti-cholinergic or cholinesterase inhibitor drugs.
Most subjects had moderate severity of disease: 1 patient in Stage
1, 2 in Stage 1.5, 11 in Stage 2, 24 in Stage 2.5, 19 in Stage 3 and
1 in Stage 4 of the modiﬁed Hoehn and Yahr classiﬁcation (Hoehn and
Yahr, 1967). Mean duration of disease was 7.03.8 (standard devi-
ation) years (range 0.5–17). Subjects with a Mini-Mental State
Examination score of 24 or less were not eligible for the study
(Folstein et al., 1975).
The Uniﬁed Parkinson’s Disease Rating Scale was performed
(Fahn and Elton, 1987). Subjects on dopaminergic drugs were exam-
ined and imaged in the morning after withholding dopaminergic drugs
overnight. Patient and control subjects underwent olfactory testing
using the University of Pennsylvania Smell Identiﬁcation Test (UPSIT,
Sensonics, Inc. Haddon Heights, NJ, USA; (Doty et al., 1984), admin-
istered by a trained examiner. The UPSIT incorporates microencapsula-
tion technology and consists of encapsulated odours, one per page
(Doty et al., 1984). There are 40 different odours and a forced
choice is made from four possible answers. Each subject underwent
a neuropsychological examination. Neuropsychological tests evaluating
different cognitive domains were used for analysis following an ap-
proach as previously reported for cognitive impairment in Parkinson’s
disease (Aarsland et al., 2009). These tests included: measures of
verbal and non-verbal memory—California Verbal Learning Test
(Delis et al., 2000) and Benton Visual Retention Test (Benton,
1974); and executive/reasoning functions—Wechsler Adult
Intelligence Scale-III Picture Arrangement test (Wechsler, 1997) and
Stroop Colour Word Interference test (Stroop, 1935), together with a
switching version of the Stroop 3 test in which subjects name the ink,
unless the word is surrounded by a box, in which case, they read the
word itself (Stroop 4). This measure makes an additional demand on
cognitive ﬂexibility (Bohnen et al., 1992). Stroop Colour Word
Interference Test scores were calculated as the time difference for
completion of the interference measures minus the non-interference
tasks; attention/psychomotor speed as absolute times on the Stroop 1
and 2 subtests (Stroop, 1935). Visuospatial function was also mea-
sured, with the Benton Judgment of Line Orientation test (Benton
et al., 1975). Composite z-scores were calculated for these different
cognitive domains (memory, executive, attention and visuospatial
functions) based on normative data from the control subjects.
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Imaging techniques
All subjects underwent brain magnetic resonance imaging and acetyl-
cholinesterase (AChE) and VMAT2 PET. Magnetic resonance imaging
was performed on a 3 Tesla Philips Achieva system (Philips, Best, The
Netherlands) utilizing an eight-channel head coil and the ‘ISOVOX’
exam card protocol primarily designed to yield isotropic spatial reso-
lution. A standard T1-weighted series of a 3D inversion
recovery-prepared turbo ﬁeld echo was performed in the sagittal
plane using repetition time/echo time/inversion time=9.8/4.6/
1041ms; turbo factor=200; single average; ﬁeld of view=
240200160mm; acquired matrix=240200. One hundred and
sixty slices were reconstructed to 1mm isotropic resolution. This se-
quence maximizes contrast among grey matter, white matter and
cerebrospinal ﬂuid and provides high-resolution delineation of cortical
and subcortical structures.
AChE and VMAT2 PET imaging were performed in 3D imaging
mode using an ECAT HR+ tomograph (Siemens Molecular Imaging,
Inc., Knoxville, TN), which acquires 63 transaxial slices (slice thick-
ness=2.4mm; intrinsic in-plane resolution=4.1mm full width at half
maximum over a 15.2cm axial ﬁeld of view). A NeuroShield (Scanwell
Systems, Montreal, Canada) head-holder/shielding unit was attached
to the patient bed to reduce the contribution of detected photon
events originating from the body outside the scanner ﬁeld of view
(Thompson et al., 2001). Prior to the dihydrotetrabenazine and
methyl-4-piperidinyl propionate injections, a 5min transmission scan
was acquired using rotating
68Ge rods for attenuation correction of
emission data using the standard vendor-supplied segmentation and
re-projection routines.
[
11C]methyl-4-piperidinyl propionate was prepared in high radio-
chemical purity (495%) by N-[
11C]methylation of piperidin-4-yl pro-
pionate using a previously described method (Snyder et al., 1998).
Dynamic PET scanning was performed for 70min immediately follow-
ing a bolus intravenous injection of 666 mega-Becquerel
(18milliCuries) of [
11C]methyl-4-piperidinyl propionate. The dose
contained less than 200mg cold methyl-4-piperidinyl propionate
mass. Emission data were collected in 16 sequential emission
scans: four30s; three1min; two2.5min; two5min; and
ﬁve10min.
No-carrier-added (+)-[
11C]dihydrotetrabenazine (250–1000Ci/mmol
at the time of injection) was prepared as reported previously (Jewett
et al., 1997). Dynamic PET scanning was performed for 60min imme-
diately following a bolus injection of 55% of 666 mega-Becquerel
(18milliCuries) of (+)-[
11C]dihydrotetrabenazine dose (containing less
than 50mg of cold dihydrotetrabenazine mass) over the ﬁrst 15–30s of
the study, while the remaining 45% of the dose was continuously
infused over the next 60min, resulting in stable arterial tracer levels
and equilibrium with brain tracer levels after 30min (Koeppe et al.,
1997). A series of 15 frame sequence of scans over 60min were
obtained as following: four30s; three1min; two2.5min;
two5min; and four10min. All subjects were studied supine,
with eyes and ears unoccluded, resting quietly in a dimly lit room.
Analysis
All image frames were spatially co-registered within subjects with a
rigid-body transformation to reduce the effects of subject motion
during the imaging session (Minoshima et al., 1993). IDL image ana-
lysis software (Research systems, Inc., Boulder, CO) was used to trace
volumes of interest manually on the magnetic resonance imaging scan,
representing the hippocampus, amygdala and the striatum. Total cor-
tical volumes of interest were deﬁned using semi-automated thresh-
olding delineation of cortical grey matter signal on the magnetic
resonance imaging scan.
AChE hydrolysis rates (k3) were estimated using the striatal volume
of interest (deﬁned by manual tracing on the magnetic resonance
imaging scan of the putamen and caudate nucleus) as the reference
input tissue (Nagatsuka et al., 2001).
Dihydrotetrabenazine images were analysed using equilibrium mod-
elling to estimate the non-displaceable binding potential (BPND), which
is equivalent to the ratio of speciﬁc (VS) to-non-displaceable (VND)
binding in each imaged voxel or target volume of interest (Koeppe
et al., 1997). We estimated speciﬁc dihydrotetrabenazine binding by
subtraction of the global neocortex value, a reference region very low
in VMAT2 binding sites, with the assumption that the non-displaceable
distribution is uniform across the brain at equilibrium (Koeppe et al.,
1999).
Standard pooled-variance t or Satterthwaite’s method of approxi-
mate t-tests (tapprox) were used for group comparisons (SAS version
9.1, SAS institute, Cary, North Carolina). Pearson correlation coefﬁ-
cients were calculated for correlation between clinical or PET variables.
Results
Olfactory and cognitive ﬁndings
There were no signiﬁcant differences in age or education between
the groups (Table 1). Patients with Parkinson’s disease had signiﬁ-
cantly reduced UPSIT scores compared to controls (Table 1).
Parkinson’s disease subjects had signiﬁcantly worse performance
on most cognitive measures compared to the control subjects
(Table 1).
Acetylcholine PET imaging ﬁndings in
Parkinson’s disease and control subjects
Analysis of the AChE PET data demonstrated reduced mean neo-
cortical, hippocampal and amygdala AChE activity in the
Parkinson’s disease group (Table 2). There were no signiﬁcant
left-right hemispheric differences for AChE activity in the patients
with Parkinson’s disease.
Relationship between olfaction, in vivo
imaging and cognitive ﬁndings
UPSIT scores correlated positively with AChE activity in the hippo-
campus (r=0.56, P50.0001; Fig. 1), amygdala (r=0.50,
P50.0001) and neocortex (r=0.46, P=0.0003). Thus, individuals
with higher UPSIT scores had higher AChE activity, and those with
lower UPSIT scores had lower AChE activity, in these brain re-
gions. Striatal VMAT2 activity correlated positively with UPSIT
scores (r=0.30, P=0.022).
Multiple regression analysis including limbic (hippocampal and
amygdala) and neocortical AChE activity and striatal VMAT2 ac-
tivity using UPSIT scores as the dependent variable demonstrated
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signiﬁcant regressor effect for limbic AChE activity (F=10.1,
P50.0001), borderline for striatal VMAT2 activity (F=1.6,
P=0.13), but no longer signiﬁcant for cortical AChE activity
(F=0.3, P=0.75).
Multiple regression analysis was performed to control for poten-
tial confounders (age, disease duration and Uniﬁed Parkinson’s
disease Rating Scale motor severity) to evaluate the main regres-
sion effect between UPSIT scores and limbic AChE activity. The
overall regression model was signiﬁcant (F=8.1, P50.0001) with
a signiﬁcant regressor effect for limbic AChE activity (F=19.2,
P50.0001) independent of signiﬁcant effects for motor severity
(F=5.0, P=0.03). Effects for age (F=0.2, P=0.70) or duration
of motor disease (F=0.7, P=0.40) were not signiﬁcant in the
model.
Higher UPSIT scores were associated with better scores on cog-
nitive measures of memory (composite memory z-score, r=0.26,
P50.05). Comparison between verbal versus non-verbal learning
demonstrates a signiﬁcant effect for episodic verbal learning
(r=0.30, P=0.023) but not for visual non-verbal memory
(r=0.18, P=0.17). There was a borderline positive correlation be-
tween the UPSIT and the Mini-Mental State Examination scores
(r=0.25, P=0.055). There were no signiﬁcant correlations be-
tween the UPSIT and visuospatial function (r=0.001, P=0.99),
attention (r=–0.05, P=0.80) or executive (r=0.1, P=0.46) func-
tion composite z-scores.
Limbic AChE activity correlated positively with executive cogni-
tive (r=0.36, P=0.006), memory (r=0.29, P=0.03), borderline
with attention (r=–0.26, P=0.054) but not with visuospatial func-
tion (r=0.04, P=0.76) composite z-scores.
Post hoc analysis
A post hoc analysis was performed to evaluate a possible nigros-
triatial dopaminergic denervation statistical ‘ﬂoor’ effect with more
advanced disease relative to its correlation with the olfactory
measures. Analysis limited to Parkinson’s disease subjects stage
Hoehn and Yahr 2 or below (n=14) demonstrated signiﬁcant cor-
relation between striatal VMAT2 activity and UPSIT (r=0.61,
P=0.02). In contrast, analysis limited to Parkinson’s disease sub-
jects Hoehn and Yahr stage 2.5 and higher demonstrated a bor-
derline trend between striatal VMAT2 activity and UPSIT scores
(r=0.25, P=0.10). Signiﬁcant correlations between limbic and
neocortical AChE activity and UPSIT scores were present in both
Parkinson’s disease severity subgroups. Analysis limited to
Parkinson’s disease subjects in stage Hoehn and Yahr 2 or below
demonstrated positive correlations between UPSIT scores and
limbic (r=0.55, P=0.04) and cortical (r=0.60, P=0.024) AChE
hydrolysis rates. Analysis limited to Parkinson’s disease subjects
Hoehn and Yahr stage 2.5 and higher demonstrated positive cor-
relations between UPSIT scores and limbic (r=0.60, P50.0001)
and cortical AChE hydrolysis rates (r=0.42, P=0.0045).
Table 1 Demographic, olfactory and cognitive measures in the Parkinson’s disease and control subjects
Parkinson’s disease (n=58) Controls (n=26) Statistical signiﬁcance
Age (year) 69.07.6 67.210.5 t=0.8; P=0.44
Education (year) 15.03.1 16.02.8 t=1.4; P=0.16
Mini-Mental State Examination 29.01.4 29.80.5 tapprox=4.0; P=0.0001
University of Pennsylvania Smell Identiﬁcation Test 16.79.0 30.38.3 t =6.6; P50.0001
California Verbal Learning Test – Immediate Memory 8.32.1 10.22.2 t=3.8; P=0.0003
California Verbal Learning Test – Short Term Memory 8.23.0 11.22.7 t=4.4; P50.0001
California Verbal Learning Test – Long Term Memory 9.43.5 11.13.0 t=4.6; P50.0001
Benton Visual Retention Test 6.12.0 7.71.0 tapprox=4.6; P50.0001
Stroop Colour Word Test 1 (s) 62.417.7 51.612.6 t=2.8; P=0.007
Stroop Colour Word Test 2 (s) 80.216.7 66.419.1 t=3.4; P=0.001
Stroop Colour Word Test 3 (s) 155.547.1 121.141.1 t=3.2; P=0.001
Stroop Colour Word Test 4 (s) 173.958.8 141.243.2 t=2.5; P=0.013
Picture Arrangement Test 11.55.0 13.03.5 tapprox=1.5; P=0.13
Judgment of Line Orientation Test 23.84.2 24.53.8 t=0.6; P=0.52
Data are mean (SD).
Table 2 Limbic and neocortical AChE hydrolysis rates (k3; min
1) and striatal VMAT2 binding potential (BPND) in the
Parkinson’s disease and control subjects
Parkinson’s disease (n=58) Controls (n=26) Statistical signiﬁcance
Neocortical AChE k3 0.0272 0.0026 0.03030.0035 t=4.6; P50.0001
Hippocampal AChE k3 0.04260.0058 0.04720.0091 tapprox=2.3; P=0.025
Amygdala AChE k3 0.05960.0096 0.06810.0156 tapprox=2.5; P=0.015
Striatal VMAT2 BPND 0.960.32 1.980.32 t=13.4; P50.0001
Data are mean (SD).
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We found a positive association between odour identiﬁcation per-
formance and a measure of forebrain cholinergic pathway integrity
in Parkinson’s disease. Diminished cholinergic innervation of the
limbic archicortex, in particular, was associated with olfactory dys-
function. This ﬁnding suggests that impaired cholinergic function
may contribute to the pathophysiology of Parkinson’s disease ol-
factory dysfunction.
Olfactory deﬁcits in Parkinson’s disease are described in odour
identiﬁcation, odour discrimination, odour threshold detection and
odour recognition memory (Mesholam et al., 1998; Haehner
et al., 2009), and these tests share considerable variance (Doty
et al., 1994). Proper interpretation of olfactory dysfunction in
these different domains requires a distinction between the cogni-
tive processes involved in an olfactory task and the physiological
olfactory element of the task. For example, odour discrimination
tasks may preferentially recruit the hippocampus, possibly reﬂect-
ing its role in the working memory element of such tasks (Kareken
et al., 2003). Odour identiﬁcation requires recognizing or naming
the odour, a long-term memory function, whereas forced-choice
threshold tests recruit short-term memory processes. These oper-
ational processes in olfactory tests will in part depend on the in-
tegrity of structures involved in higher order cognitive or memory
processing, such as the limbic cortex (Larsson et al., 2004; Wang
et al., 2005). For example, regional grey matter atrophy of the
paralimbic cortex has been found to correlate with the presence of
olfactory dysfunction in early Parkinson’s disease whereas atrophy
of the limbic cortex correlated with olfactory deﬁcits in patients
with moderately advanced Parkinson’s disease (Wattendorf et al.,
2009). We found a robust positive association between limbic
AChE activity and performance on an odour identiﬁcation task in
a population of non-demented subjects with Parkinson’s disease
(mean Mini-Mental State Examination score of 29.0).
Furthermore, the association between limbic AChE activity and
memory performance was only modest, implying that our ﬁndings
cannot be explained on the basis of memory deﬁcits alone.
Hippocampal and entorhinal pathology is an early feature of
Alzheimer’s disease and odour identiﬁcation deﬁcits occur early
in the disease course. Alzheimer disease olfactory defects reﬂect
deﬁcits of odour cognitive processing rather than odour detection,
which is not altered until later in Alzheimer’s disease (Serby et al.,
1991). We found that the UPSIT had more selective association
with performance on episodic verbal learning. This is likely to re-
ﬂect the speciﬁc verbal cognitive functions involved in odour iden-
tiﬁcation. Episodic memory impairment is a hallmark of
Alzheimer’s disease, and loss of basal forebrain cholinergic neurons
that innervate the hippocampus and neocortex is an early and key
feature of Alzheimer’s disease (Yan and Feng, 2004). Post-mortem
studies describe marked regional variations in the extent of cho-
linergic losses with the temporal lobe displaying the most signiﬁ-
cant losses of cholinergic ﬁbers (Geula and Mesulam, 1996). These
ﬁndings provide evidence for selective loss of the cholinergic sep-
tohippocampal pathway and subregions within the nucleus basalis
of Meynert, namely the posterior portion that innervate the tem-
poral lobe, including the amygdala and the hippocampal formation
(Emre et al., 1993; Lehericy et al., 1993; Geula and Mesulam,
1996). Our ﬁndings of more robust correlation between deﬁcits
in odour identiﬁcation and limbic than neocortical AChE activity
are concordant with these observations in Alzheimer’s disease.
Involvement of the limbic cholinergic system in olfactory pro-
cessing is also supported by animal studies. For example, disrup-
tion of normal cholinergic function alters odour memory, including
both habituation to a familiar odour and odour-based social rec-
ognition (Hunter and Murray, 1989; Paolini and McKenzie, 1993,
1996; Berger-Sweeney et al., 2000), short-term memory for
odours (Ravel et al., 1992, 1993, 1994) and acquisition of a com-
plex odour discrimination task (De Rosa et al., 2001; Mandairon
et al., 2006). Systemic physostigmine enhances discrimination be-
tween extremely similar odours in rats (Doty et al., 1999).
Conversely, systemic scopolamine impairs olfactory perceptual
learning (Fletcher and Wilson, 2002). Local injection of scopolam-
ine in the hippocampal formation and prelimbic cortices impairs
memory for socially transmitted food preference in rats
(Carballo-Marquez et al., 2009). Selective lesioning of basal fore-
brain cholinergic neurons is associated with anterograde and retro-
grade deﬁcits in a social transmission of food preference task in
rats (Vale-Martinez et al., 2002), and lesions of the horizontal limb
of the diagonal band of Broca impair olfactory memory (Linster
and Hasselmo, 2000). There is a single human study showing that
the AChE inhibitor drug donepezil improves odour identiﬁcation in
patients with Alzheimer’s disease, providing preliminary clinical
support for a cholinergic component of olfactory processing in
neurodegeneration (Velayudhan and Lovestone, 2009).
There is increasing evidence that cholinergic denervation occurs
early in Parkinson’s disease and progressive cholinergic dener-
vation is associated with the presence of dementia in this disorder
(Shimada et al., 2009). Lewy ﬁrst identiﬁed the eponymous Lewy
body in neurons of the nucleus basalis of Meynert (Lewy, 1913),
the source of cholinergic innervation of the cerebral cortex. In the
Braak et al. (2003) staging scheme of Parkinson’s disease path-
ology, nigral and magnocellular basal forebrain pathology occur
Figure 1 Scatter plot of the relationship between hippocampal
AChE k3 hydrolysis (min
1) rates and UPSIT score in the
Parkinson’s disease subjects (r=0.56, P50.0001).
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niﬁcant cholinergic denervation in early drug naı ¨ve Parkinson’s
disease subjects without cognitive symptoms (Shimada et al.,
2009). We found evidence of cholinergic denervation that corre-
lated with cognitive performance on memory and executive tasks
in patients with Parkinson’s disease without dementia. In vivo
imaging studies have also shown that the presence of dementia
in Parkinson’s disease is associated with more severe and wide-
spread cholinergic denervation compared to Parkinson’s disease
without dementia (Kuhl et al., 1996; Shinotoh et al., 1999;
Bohnen et al., 2003; Hilker et al., 2005). These imaging results
are consistent with post-mortem evidence that basal forebrain
cholinergic system degeneration appears early in Parkinson’s dis-
ease and worsens with the appearance of dementia (Ruberg et al.,
1986). A post-mortem study found greater reductions of AChE in
the frontal cortex of demented (68%) compared with
non-demented (35%) patients with Parkinson’s disease
(Ruberg et al., 1986). Furthermore, cognitive impairment has
been found to correlate with cortical choline acetyltransferase
levels, but not with the extent of plaque or tangle formation in
Parkinson’s disease (Perry et al., 1985; Mattila et al., 2001).
Similarly, Mattila et al. (2001) found that cognitive decline in
Parkinson’s disease was associated with lower cortical choline
acetyltransferase levels, even in the absence of Alzheimer’s disease
pathology. Therefore, impairment or degeneration of the cholin-
ergic system may play a signiﬁcant role in the cognitive decline in
Parkinson’s disease (Perry et al., 1985).
We previously reported signiﬁcant correlations between UPSIT
scores and hippocampal, amygdala and striatal dopaminergic
activity using a highly speciﬁc dopamine transporter PET radio-
ligand, [
11C]()-2-b-Carbomethoxy-3-b-(4-ﬂuorophenyl)tropane,
in (very) early Parkinson’s disease, including drug-naı ¨ve subjects
(Bohnen et al., 2007, 2008). A limitation of the present study is
that the VMAT2 ligand cannot be used for speciﬁc assessment of
extra-striatal dopaminergic innervation as this ligand fails to dis-
criminate between dopaminergic and serotonergic or adrenergic
innervation of the hippocampus and amygdala. Furthermore, the
Parkinson’s disease subjects enrolled in the present study had
lower smell performance and approximately twice the duration
of disease and clinical severity of motor impairment than patients
with Parkinson’s disease from our previous study. As there may be
a ‘ﬂoor’ effect underlying the relationship between dopaminergic
denervation and odour identiﬁcation, we performed a subgroup
analysis stratiﬁed for severity of disease and found signiﬁcant cor-
relations between striatal VMAT2 activity and UPSIT scores in the
subjects with mild disease but not in those with more advancing
disease. These data provide supportive evidence for the presence
of a ‘ﬂoor’ effect with respect to hyposmia and nigrostriatal dopa-
minergic denervation in advancing Parkinson’s disease. In addition,
multiple regression analysis demonstrated signiﬁcant regression for
odour identiﬁcation scores and limbic AChE activity while regres-
sion with striatal VMAT2 activity was only borderline signiﬁcant
in the present study. We did not ﬁnd evidence of a cholinergic
denervation ‘ﬂoor’ effect relative to odour identiﬁcation in the
present study. Thus, cholinergic denervation may be a more
important determinant of odour identiﬁcation deﬁcits than
nigrostriatal dopaminergic denervation in patients with advancing
Parkinson’s disease.
Parkinson’s disease is now being recognized as a multi-system
neurodegeneration syndrome (Langston, 2006). It is plausible that
hyposmia in Parkinson’s disease may have multiple components
including olfactory bulb and primary olfactory cortex components,
and limbic dysfunction secondary to dopaminergic, cholinergic and
other denervations. Olfactory impairments have been shown in an
animal model with reduced monoaminergic storage capacity
(Taylor et al., 2009). Dopaminergic effects may be more signiﬁ-
cant in hyposmia of early Parkinson’s disease because dopamin-
ergic, unlike cholinergic, denervation is uniformly and severely
present in all subjects with early prototypical Parkinson’s disease.
In contrast, cholinergic denervation is more heterogeneous and
more severe loss of smell may reﬂect cholinergic denervation in
the subset of patients with Parkinson’s disease and incipient cog-
nitive impairment. Our ﬁndings cannot be explained by tandem
multi-system neurodegeneration as the cholinergic denervation
hyposmia ﬁnding was independent from the effects of age, dur-
ation of disease, severity of motor disease or degree of nigrostria-
tal dopaminergic denervation.
We conclude that cholinergic denervation, especially of the
limbic archicortex, is a more robust determinant of odour identiﬁ-
cation deﬁcits than nigrostriatal dopaminergic denervation in sub-
jects with moderately severe Parkinson’s disease. Future
longitudinal research is needed to determine whether lower
smell performance predicts development of dementia in
Parkinson’s disease.
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